×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Acurx Pharmaceuticals Stock Forecast, Price & News

$3.75
-0.04 (-1.06%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.63
$3.82
50-Day Range
$2.42
$4.00
52-Week Range
$2.33
$6.35
Volume
10,508 shs
Average Volume
22,854 shs
Market Capitalization
$38.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Acurx Pharmaceuticals Stock Forecast (MarketRank)

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
220.0% Upside
$12.00 Price Target
Short Interest
Healthy
0.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.70 out of 5 stars

Medical Sector

843rd out of 1,428 stocks

Pharmaceutical Preparations Industry

421st out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ACXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

ACXP Stock News Headlines

Acurx Pharmaceuticals Tops Q1 EPS by 7c
Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable. I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually). I grew my $50K into $5.3M
Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable. I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually). I grew my $50K into $5.3M
Acurx Pharmaceuticals to Join the Russell Microcap Index®
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACXP
Fax
N/A
Employees
3
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
7/02/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+220.0%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-12.75 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.23 per share

Miscellaneous

Free Float
N/A
Market Cap
$38.49 million
Optionable
Not Optionable
Beta
N/A














Acurx Pharmaceuticals Frequently Asked Questions

Should I buy or sell Acurx Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Acurx Pharmaceuticals stock.
View analyst ratings for Acurx Pharmaceuticals
or view top-rated stocks.

What is Acurx Pharmaceuticals' stock price forecast for 2022?

1 brokerages have issued 12-month price targets for Acurx Pharmaceuticals' shares. Their ACXP stock forecasts range from $12.00 to $12.00. On average, they anticipate Acurx Pharmaceuticals' share price to reach $12.00 in the next year. This suggests a possible upside of 220.0% from the stock's current price.
View analysts' price targets for Acurx Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Acurx Pharmaceuticals' stock performed in 2022?

Acurx Pharmaceuticals' stock was trading at $4.3214 at the start of the year. Since then, ACXP stock has decreased by 13.2% and is now trading at $3.75.
View the best growth stocks for 2022 here
.

When is Acurx Pharmaceuticals' next earnings date?

Acurx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Acurx Pharmaceuticals
.

How were Acurx Pharmaceuticals' earnings last quarter?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) posted its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.07.
View Acurx Pharmaceuticals' earnings history
.

Who are Acurx Pharmaceuticals' key executives?

Acurx Pharmaceuticals' management team includes the following people:

When did Acurx Pharmaceuticals IPO?

(ACXP) raised $15 million in an initial public offering on Friday, June 25th 2021. The company issued 2,500,000 shares at $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities acted as the underwriters for the IPO.

What is Acurx Pharmaceuticals' stock symbol?

Acurx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACXP."

How do I buy shares of Acurx Pharmaceuticals?

Shares of ACXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acurx Pharmaceuticals' stock price today?

One share of ACXP stock can currently be purchased for approximately $3.75.

How much money does Acurx Pharmaceuticals make?

Acurx Pharmaceuticals (NASDAQ:ACXP) has a market capitalization of $38.49 million. The company earns $-12.75 million in net income (profit) each year or ($1.52) on an earnings per share basis.

How many employees does Acurx Pharmaceuticals have?

Acurx Pharmaceuticals employs 3 workers across the globe.

How can I contact Acurx Pharmaceuticals?

The official website for Acurx Pharmaceuticals is www.acurxpharma.com. The company can be reached via phone at 917-533-1469 or via email at davidluci@acurxpharma.com.

This page (NASDAQ:ACXP) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.